Sendero Wealth Management LLC Acquires 2,699 Shares of UnitedHealth Group Incorporated $UNH

Sendero Wealth Management LLC increased its stake in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 76.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,239 shares of the healthcare conglomerate's stock after acquiring an additional 2,699 shares during the period. Sendero Wealth Management LLC's holdings in UnitedHealth Group were worth $1,946,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Valeo Financial Advisors LLC raised its holdings in UnitedHealth Group by 1,726.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 253,360 shares of the healthcare conglomerate's stock valued at $79,041,000 after buying an additional 239,486 shares during the period. Vantage Investment Partners LLC raised its stake in shares of UnitedHealth Group by 105.8% in the second quarter. Vantage Investment Partners LLC now owns 289,696 shares of the healthcare conglomerate's stock valued at $90,376,000 after acquiring an additional 148,945 shares during the period. Plimoth Trust Co. LLC grew its holdings in UnitedHealth Group by 3.4% during the 2nd quarter. Plimoth Trust Co. LLC now owns 8,435 shares of the healthcare conglomerate's stock valued at $2,631,000 after purchasing an additional 275 shares during the last quarter. Marks Group Wealth Management Inc lifted its stake in UnitedHealth Group by 2.7% in the second quarter. Marks Group Wealth Management Inc now owns 19,660 shares of the healthcare conglomerate's stock worth $6,133,000 after purchasing an additional 524 shares during the last quarter. Finally, Woodmont Investment Counsel LLC grew its stake in shares of UnitedHealth Group by 9.5% during the second quarter. Woodmont Investment Counsel LLC now owns 20,368 shares of the healthcare conglomerate's stock valued at $6,354,000 after buying an additional 1,760 shares during the last quarter. Hedge funds and other institutional investors own 87.86% of the company's stock.

UnitedHealth Group Trading Up 1.8%

UNH opened at $360.17 on Monday. UnitedHealth Group Incorporated has a 12 month low of $234.60 and a 12 month high of $630.73. The stock has a fifty day moving average price of $307.84 and a 200-day moving average price of $353.45. The firm has a market cap of $326.20 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.34 and a beta of 0.47. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last announced its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 EPS for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The firm had revenue of $111.62 billion during the quarter, compared to the consensus estimate of $111.75 billion. During the same quarter in the prior year, the firm posted $6.80 earnings per share. The business's revenue for the quarter was up 12.9% compared to the same quarter last year. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. As a group, equities research analysts anticipate that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.

UnitedHealth Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 23rd. Stockholders of record on Monday, September 15th were given a $2.21 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $8.84 dividend on an annualized basis and a dividend yield of 2.5%. UnitedHealth Group's dividend payout ratio (DPR) is presently 38.30%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. KeyCorp dropped their price objective on UnitedHealth Group from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Barclays lifted their price objective on shares of UnitedHealth Group from $337.00 to $352.00 and gave the company an "overweight" rating in a report on Thursday, September 4th. Oppenheimer dropped their target price on shares of UnitedHealth Group from $400.00 to $325.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 30th. Royal Bank Of Canada dropped their price objective on UnitedHealth Group from $355.00 to $286.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 30th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of UnitedHealth Group in a report on Saturday, September 27th. Sixteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat.com, UnitedHealth Group presently has a consensus rating of "Hold" and a consensus price target of $358.95.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.